证券记录 · 已归档季度
GRAL
GRAIL Inc. · Healthcare · Medical - Diagnostics & Research
15被追踪持有人
n/aΔ持有人
4.39M持有股份
$67.54M报告持仓市值
+0新建仓位
−0清仓
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 110 | +3 | 19.61M | $1.34B | +13 | −10 |
| Q1 2026 | 110 | -6 | 18.56M | $959.35M | +4 | −11 |
| Q4 2025 | 117 | +2 | 17.78M | $1.52B | +3 | n/a |
| Q3 2025 | 18 | +1 | 10.99M | $649.07M | +2 | −2 |
| Q2 2025 | 15 | -1 | 10.50M | $537.63M | +1 | −2 |
| Q1 2025 | 13 | +1 | 6.08M | $155.14M | +2 | −1 |
| Q4 2024 | 12 | +2 | 5.32M | $94.90M | +3 | −1 |
| Q3 2024 | 9 | -6 | 3.74M | $51.49M | n/a | −6 |
| Q2 2024 | 15 | n/a | 4.39M | $67.54M | n/a | n/a |
持有人 · Q2 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | PRIMECAP Management ✦ | 1.87M | n/a | $28.67M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 798.02K | n/a | $12.27M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (被动) | 421.77K | n/a | $6.48M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Norges Bank ✦ (被动) | 351.83K | n/a | $5.41M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 303.85K | n/a | $4.67M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Millennium Management ✦ | 246.27K | n/a | $3.79M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Marshall Wace ✦ | 80.95K | n/a | $1.24M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 8 | Soros Fund Management ✦ | 75.00K | n/a | $1.15M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 68.91K | n/a | $1.06M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Capital World Investors ✦ | 67.14K | n/a | $1.03M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Renaissance Technologies ✦ | 60.80K | n/a | $934,557 | 0.0% | n/c | 1 | SEC ↗ |
| 12 | GAMCO Investors ✦ | 20.00K | n/a | $307,400 | 0.0% | n/c | 1 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 19.14K | n/a | $295,000 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 14 | AQR Capital Management ✦ | 14.95K | n/a | $226,566 | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 15 | Baillie Gifford ✦ | 606 | n/a | $9,314 | 0.0% | n/c | 1 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 1 持有人, 9.40K 股份, $485 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Oct 15
Ofman Joshua J.
Officer, Director · 6.03K 股 · $830,465
Oct 15
Ofman Joshua J.
Officer, Director · 7.05K 股 · $964,946
Oct 15
Ofman Joshua J.
Officer, Director · 2.11K 股 · $293,394
Oct 15
Ofman Joshua J.
Officer, Director · 400 股 · $53,247
Oct 15
Ofman Joshua J.
Officer, Director · 1.00K 股 · $134,384
Oct 15
Ofman Joshua J.
Officer, Director · 3.40K 股 · $460,508
Oct 05
Freidin Aaron
Officer · 23.62K 股 · $3.46M
Oct 05
Partridge Andrew John
Officer · 7.87K 股 · $1.15M
Sep 21
Ofman Joshua J.
Officer, Director · 10.00K 股 · $1.10M
Sep 21
Ofman Joshua J.
Officer, Director · 2.10K 股 · $211,429
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Aug 13
SC 13G/A: FARALLON CAPITAL MANAGEMENT, L.L.C.
Aug 07
SC 13G: STATE STREET CORP
Aug 06
SC 13G/A: PRIMECAP MANAGEMENT CO/CA/
Jul 28
SC 13G/A: BlackRock, Inc.
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2024 ·
方法论 ·
通过API获取此数据